Drs. Peter Richardson and George Wan of Mallinckrodt Pharmaceuticals discussed new data on terlipressin for HRS-AKI. Dr. Pranav Garimella, CMO of the American Kidney Fund, discussed AMKD awareness and the importance of APOL1 gene variants. Joel Topf spoke with Mini Michael about the ILLUMINATE-B study of lumasiran for PH1 in infants and young children. We spoke with ALIGN study investigator Richard Lafayette, MD, upon the FDA's accelerated approval of atrasentan for IgAN. Joel Topf spoke with dietitian Melanie Betz about potassium, oxalate, and other renal nutrition concerns. Joel Topf spoke with Areef Ishani about kidney stone outcomes from the Diuretic Comparison Project, a study of US veterans. Joel Topf spoke to Seldin Award winner Roger Rodby at the National Kidney Foundation Spring Clinical Meetings 2025. Joel Topf spoke with Kathleen Liu about acute kidney injury and other topics ahead of her Massry lecture at SCM25. We spoke to David M. Hume Award winner Bradley Warady, MD, at the National Kidney Foundation Spring Clinical Meetings 2025. Joel Topf spoke to onconephrologist Meghan Sise about her carboplatin dosing research at SCM25. Joel Topf caught up with James Tumlin at NKF SCM25 to talk about Dr. Tumlin's late-breaking abstract on sparsentan in FSGS. Joel Topf spoke with Lazarus Award winner Jeffrey Perl at the National Kidney Foundation Spring Clinical Meetings 2025. Joel Topf spoke with Connie Rhee at SCM25 about her study on cognitive function with dialysis vs conservative CKD management. Joel Topf spoke with Bradley Marder of Amgen about gout studies at the NKF Spring Clinical Meetings 2025. Joel Topf spoke to Excellence in Transplantation Award winner Jayme Locke at the National Kidney Foundation SCM25. Dr. Thomas Pham spoke to us about kidney donation during National Donate Life Month. Suphamai Bunnapradist discussed the phase 3 TRANSCEND study of felzartamab to treat late AMR after kidney transplantation. Faith Lynch, president-elect of ANNA, discussed her upcoming term and challenges faced by nephrology nurses. Babak Orandi spoke with us about a study showing that GLP-1 drugs have benefits for kidney transplant recipients with T2D. Eledon Pharmaceuticals CEO David-Alexandre Gros, MD, spoke about the role of CD40L blocker tegoprubart in transplantation.